Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

Ubiquitin‐Independent Degradation: An Emerging PROTAC Approach?

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

PROTAC targeted protein degraders: the past is prologue

Targeted protein degradation: expanding the toolbox

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation

Targeted protein degradation directly engaging lysosomes or proteasomes

Recent advances in targeted protein degraders as potential therapeutic agents

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Novel approaches to targeted protein degradation technologies in drug discovery

The Present and Future of Novel Protein Degradation Technology

Targeted protein degradation in drug development: Recent advances and future challenges

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Targeted protein degradation: mechanisms, strategies and application

Bivalent Ligands for Protein Degradation in Drug Discovery